$9.91
2.16% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Instil Bio Inc Share price

$9.91
-1.13 10.20% 1M
+2.45 32.85% 6M
+2.29 30.05% YTD
-1.06 9.63% 1Y
-373.89 97.42% 3Y
-390.09 97.52% 5Y
-390.09 97.52% 10Y
Nasdaq, Closing price Thu, Jun 27 2024
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Key figures

Market capitalization $64.45m
Enterprise Value $-3.53m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.05
P/B ratio (TTM) P/B ratio 0.31
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-72.95m
Free cash flow (TTM) Free cash flow $-73.96m
Cash position $153.79m
EPS (TTM) EPS $-18.96
P/E ratio expected negative
Short interest 0.36%
Show more

Is Instil Bio Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Instil Bio Inc Share analysis

Unlock scores for free

Analyst opinions

3 Analysts have issued a Instil Bio Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst opinions

3 Analysts have issued a Instil Bio Inc forecast:

Buy
67%
Hold
33%

Financial data from Instil Bio Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 3.82 3.82
39% 39%
-
-3.82 -3.82
39% 39%
-
- Selling and administrative expenses 39 39
18% 18%
-
- Research and development costs 26 26
79% 79%
-
-69 -69
61% 61%
-
- Depreciation and amortization 3.82 3.82
39% 39%
-
EBIT (operating result) EBIT -73 -73
60% 60%
-
Net profit -123 -123
45% 45%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Instil Bio Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Instil Bio Inc Share News

Neutral
GlobeNewsWire
about 2 months ago
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update.
Neutral
GlobeNewsWire
3 months ago
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.
Neutral
GlobeNewsWire
5 months ago
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update.
More Instil Bio Inc News

Company profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Bronson Crouch
Employees 49
Founded 2018
Website www.instilbio.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now